Novo Nordisk has sued about a dozen spas, clinics and pharmacies, over unapproved versions of semaglutide, the active ingredient for its Type 2 diabetes drug Ozempic and weight loss therapy Wegovy.
Read the full post on Becker's Hospital Review - Healthcare News
